Abstract
This project is a continuation from a previous investigation from 2012. The objective is an at home, Point of Care testing device to monitor average glucose status of diabetic patients which has been proven more reliable. The technology involves a complex assembly of enzymes, hemolyzing agents, and electrodes, such that one drop of whole blood can be rapidly assayed for Hemoglobin A1c – a long term indicator of average day to day blood glucose levels.
Specific to the aspect of this work, two alternative proteinase enzymes, were compared. Our results clearly demonstrated that Proteinase K (Roche) is superior in its activity. Furthermore, the Proteinase K can be further potentiated by covalent derivatives using conventional polymeric substances well known to the pharmaceutical industry. The one selected was polyethylene glycol (PEG). Based upon the patent literature of Mountain View Pharm, authors of US Patent (7229810 B2). Our investigation formulated a synthetic strategy for a novel Enzyme- Polymeric conjugate bi-functional in nature. Our results clearly show that this Proteinase K- Polymeric conjugate had increased stability (confirmed by mass spectrometry), and had superior activity.
In order to make our findings compatible to the Medical Device, we formulated a strategy to covalently couple the conjugate to a silica based colloid that was confirmed by Indirect Infra-Red Spectroscopy. This allows for superior manufacture of the device and prevents enzyme migration off target. The Enzyme –Polymer- Silicon Dioxide colloid conjugate does retain the superior enzymatic activity while also provides stability and compatibility to the device architecture.
Faculty Sponsors
Dr. Terry McCaffrey
Project Type
Event
Location
Alvin Sherman Library
Start Date
4-4-2014 1:00 PM
End Date
4-4-2014 5:30 PM
Development of a Model Medical Device Using Highly Active Derivatized Proteinase Enzyme
Alvin Sherman Library
This project is a continuation from a previous investigation from 2012. The objective is an at home, Point of Care testing device to monitor average glucose status of diabetic patients which has been proven more reliable. The technology involves a complex assembly of enzymes, hemolyzing agents, and electrodes, such that one drop of whole blood can be rapidly assayed for Hemoglobin A1c – a long term indicator of average day to day blood glucose levels.
Specific to the aspect of this work, two alternative proteinase enzymes, were compared. Our results clearly demonstrated that Proteinase K (Roche) is superior in its activity. Furthermore, the Proteinase K can be further potentiated by covalent derivatives using conventional polymeric substances well known to the pharmaceutical industry. The one selected was polyethylene glycol (PEG). Based upon the patent literature of Mountain View Pharm, authors of US Patent (7229810 B2). Our investigation formulated a synthetic strategy for a novel Enzyme- Polymeric conjugate bi-functional in nature. Our results clearly show that this Proteinase K- Polymeric conjugate had increased stability (confirmed by mass spectrometry), and had superior activity.
In order to make our findings compatible to the Medical Device, we formulated a strategy to covalently couple the conjugate to a silica based colloid that was confirmed by Indirect Infra-Red Spectroscopy. This allows for superior manufacture of the device and prevents enzyme migration off target. The Enzyme –Polymer- Silicon Dioxide colloid conjugate does retain the superior enzymatic activity while also provides stability and compatibility to the device architecture.
